Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies gene variants in people with multiple myeloma or MGUS

Checks gene changes in GBA and PSAP in adults with myeloma or MGUS.

Plain-language title generated from the registry record
Registry title: Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

Key facts

Where
Rouen, FranceSee the 2 sites

Where in France

  • Centre Henri BecquerelRouen, FranceNot yet recruiting
  • University Rouen HospitalRouen, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Rouen
Trial code
NCT06559033
Record updated
10 June 2026
Original description
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.Read full original descriptionShow less

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.

Inclusion: Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement); Membership of a social security scheme; Adult having read and understood the information letter and signed the consent form.

Exclusion: Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship.

ClinicalTrials.gov NCT06559033